News & Events about Ventyx Biosciences Inc.
Fool.com Headlines
1 year ago
The company has several promising autoimmune therapies.On Monday, shares of Ventyx Biosciences (NASDAQ: VTYX) closed 22.87% higher than they did last week. The clinical-stage biotech hit more than $40 a share for the first time since March 10.Ventyx focuses on therapies to treat inflammatory ...
Ventyx Biosciences, Inc. (NASDAQ:VTYX Get Rating) insider William J. Sandborn sold 3,487 shares of the firms stock in a transaction that occurred on Thursday, June 15th. The stock was sold at an average price of $34.15, for a total value of $119,081.05. Following the transaction, the ...
Ventyx Biosciences (NASDAQ:VTYX Get Rating) had its price target trimmed by Oppenheimer from $65.00 to $62.00 in a research report report published on Friday, Benzinga reports. The brokerage currently has an outperform rating on the stock. Oppenheimer also issued estimates for Ventyx ...
Ventyx Biosciences, Inc. (NASDAQ:VTYX Get Rating) Stock analysts at Oppenheimer issued their FY2026 EPS estimates for shares of Ventyx Biosciences in a report issued on Sunday, March 19th. Oppenheimer analyst J. Jones forecasts that the company will post earnings per share of ($2.75...
ENCINITAS, Calif., March 24, 2023 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (Ventyx), a clinical-stage biopharmaceutical company focused on advancing novel oral therapies that address a broad range of inflammatory diseases with significant unmet medical need, today announced that ...